Terms ending in 2034
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,518,017 | Purification of Intermediates Used in the Preparation of Heterobifunctional Linkers In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,353,127 | Methods of Preparation of Conjugates In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,637,547 | Monoclonal Antibodies for Detection of Folate Receptor 1 In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,017,578 | Methods of Treating Cancer in a Patient by Administering ANTI-FOLATE-RECEPTOR-1 (FOLR1) Antibodies In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,544,230 | Methods of Using Antibodies to Detect Folate Receptor 1 (FOLR1) In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,198,736 | A Method for Identifying an Ovarian Cancer in a Subject Likely to Respond to Anti-Folate Receptor 1 (FOLR1) Antibody In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,932,701 | Method for Increasing the Efficacy of Cancer Therapy by Administering an ANTI-FOLR1 Immunoconjugate In force · High confidence | ImmunoGen, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.